Lloyd L Thompson Iii, MD | |
195 Industrial Pkwy, Nvrh Corner Medical, Lyndon, VT 05849 | |
(802) 748-9501 | |
Not Available |
Full Name | Lloyd L Thompson Iii |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 195 Industrial Pkwy, Lyndon, Vermont |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154352672 | NPI | - | NPPES |
0004762 | Medicaid | VT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 042-0004895 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Lloyd L Thompson Iii, MD Po Box 83, Lyndonville, VT 05851-0083 Ph: (802) 748-9501 | Lloyd L Thompson Iii, MD 195 Industrial Pkwy, Nvrh Corner Medical, Lyndon, VT 05849 Ph: (802) 748-9501 |
News Archive
"One month after [USAID] announced the FWD (famine, war, and drought) public awareness campaign at the Social Good summit, they officially launched the campaign across the country though celebrity public service announcements (PSAs) developed with the Ad Council," according to a post in the Department of State's "DipNote" blog.
What do a patient with obsessive compulsive disorder (OCD), a basketball star, and an animal in captivity have in common? According to new research from Tel Aviv University, they share a clear behavioral link that reduces stress.
Current cardiovascular valve or blood vessel implants are generally associated with a number of complications, have limited efficacy over time, and may necessitate repeated interventions over a patient's lifetime, especially when implanted in a young child.
Neurologists at Wake Forest University Baptist Medical Center have found that many patients diagnosed with multiple sclerosis (MS) are not taking or being prescribed drugs approved to treat the disease.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
› Verified 6 days ago
Dr. Joyce M Dobbertin, M.D.,D.C. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: Nvrh Corner Medical, 195 Industrial Pkwy, Lyndon, VT 05849 Phone: 802-748-9501 | |
Susan L Gresser, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: Nvrh Corner Medical, 195 Industrial Pkwy, Lyndon, VT 05819 Phone: 802-748-9501 | |
Brigitte France Dargis, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 195 Industrial Parkway, Nvrh Corner Medical, Lyndon, VT 05849 Phone: 802-748-9501 Fax: 802-748-3420 |